The stock is in a sustained uptrend, evidenced by a 1-year price change of +42.35% and a YTD gain of +12.94%. With a current price of $41.01, it is trading at approximately 95% of its 52-week high of $43.08, indicating strong momentum but also proximity to a key resistance level that may signal potential overextension. The stock's positioning near the top of its 52-week range suggests investor optimism is largely priced in, though a decisive breakout above $43.08 would confirm a continuation of the bullish trend. Recent short-term momentum is positive but shows signs of divergence from the broader market; the stock gained 6.91% over the past month, outperforming the SPY's 5.49% gain, yet it underperformed over the last three months with a gain of only 2.40% versus the SPY's 7.73% rise. This 3-month underperformance, coupled with a relative strength reading of -5.33, suggests the stock may be consolidating or experiencing a temporary pullback within its longer-term uptrend, potentially offering a entry point for momentum investors. Key technical support is anchored at the 52-week low of $27.81, while immediate resistance sits at the 52-week high of $43.08. A breakdown below the recent low of $36.10 from March 20th would signal a potential trend reversal. The stock's beta of 0.789 indicates it is approximately 21% less volatile than the broader market, which is notable for a REIT and suggests it may offer a more defensive profile during market downturns, though its recent price swings show it is not immune to sector-specific volatility.

Revenue growth has been robust and accelerating; Q4 2025 revenue reached $135.05 million, representing a year-over-year growth rate of 117.13% compared to Q4 2024. Sequentially, revenue grew from $71.65 million in Q1 2025 to $135.05 million in Q4 2025, indicating a strong multi-quarter expansion driven by acquisitions and organic lease escalations. This trajectory underscores the company's successful external growth strategy and the underlying demand strength in its healthcare property portfolio. Profitability is solid and margins are expanding significantly. Net income for Q4 2025 was $111.29 million, yielding a net margin of 82.41%, while the gross margin stood at 58.93%. Comparing to the prior-year Q4, net income more than doubled from $52.14 million, and the net margin expanded from 83.82% to 82.41%, demonstrating high and stable profitability. The operating margin for the latest quarter was 64.10%, reflecting the efficiency of its triple-net lease model where most operating costs are passed to tenants. The balance sheet is healthy with a conservative leverage profile. The debt-to-equity ratio is a low 0.22, indicating minimal financial risk and ample capacity for future acquisitions. Free cash flow on a trailing twelve-month basis is $379.04 million, providing strong internal funding for dividends and growth. Return on equity (ROE) is 7.94%, and the current ratio is 1.54, showing sufficient liquidity. The combination of strong cash generation, low debt, and high margins paints a picture of a financially resilient company.